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Giuseppe MercurodCardiovascular disease is the leading cause of death in
women in western countries. Despite preventive strategies,
in the past decades, the incidence of cardiovascular events
has shown a decline in men but a rise in women, matching
the growth of the population of postmenopausal women.
Several epidemiological findings suggest the causative
pathophysiological role of ovarian hormone deficiency in
the development of cardiovascular disease in women.
Observational and randomized studies have suggested that
hormone replacement therapy in early postmenopause
could be beneficial from a cardiovascular point of view.
Conversely, aging, time since menopause and presence of
cardiovascular risk factors or cardiovascular disease may
decrease its efficacy and increase the risk of cardiovascular
events. It is plausible that the unfavorable effects of the
estrogen/progestin combination used in the randomized
studies are not related to the hormone preparation per se
but rather to the use of hormones in the less receptive
group of women, older and with cardiovascular risk factors.
Clinical judgment, choice of the right dose and estrogen/
progestin combination are of pivotal importance to1558-2027  2008 Italian Federation of Cardiologymaximize the beneficial effect of estrogen replacement
therapy/hormone replacement therapy, especially if given
within a reasonable time after themenopause to the women
who need the therapy for the relief of menopausal
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Cardiovascular disease (CVD) is the primary cause of
death in women in western countries and in Europe;
more than one of two women dies from coronary heart
disease (CHD) and stroke [1]. Although in the past
40 years, the age-adjusted mortality for cardiovascular
disease has declined, the temporal trends of the inci-
dence of CHD and cerebrovascular events have shown a
decline in men but a rise in women, matching the growth
of the population of postmenopausal women. Several
epidemiological findings suggest the causative pathoge-
netic role of ovarian hormone deficiency in the develop-
ment of CVD in women. Indeed, CVD risk increases after
the menopause and, at any age, postmenopausal women
have a significantly higher incidence of CVD compared
with normomenstruatingwomen [2,3].The postmenopau-
sal increase in cardiovascular disease after the menopauseis also matched by the increase in incidence of other
diseases, such as osteoporosis and dementia, which are
influenced by estrogen deficiency. These diseases were
uncommon inwomen until few decades ago. This was due
to the fact that until the ’60–70s the population of post-
menopausal women was small. Indeed, only in the recent
years, with the sizeable increase in female life expectancy,
there has been a sizeable proportion of postmenopausal
women and therefore the manifestation of diseases that
were rare until few decades ago.
Despite the wealth of studies proving the effect of
estrogens [estrogen replacement therapy (ERT)] and
estrogen–progestin associations [hormone replacement
therapy (HRT)] on cardiovascular functions and surro-
gate CVD end points and despite the suggestions of a
significant cardiovascular benefit of HRT gathered byDOI:10.2459/JCM.0b013e328313e979
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menopausal women, the results of recent randomized
trials conducted with a fixed HRT formulation, not
marketed in Italy, in populations of predominantly
elderly postmenopausal women [4–13] failed to show a
cardioprotective effect of ERT/HRT [13,14]. Further-
more, the Women’s Health Initiative (WHI) studies have
suggested a possible increase in cardiovascular disease in
late postmenopausal women receiving ERT/ERT and
have led to a contraindication of ERT/HRT also in early
postmenopausal women. More recently, the WHI has
reported that the effect of ERT/HRT differs according to
time since menopause and age with a possible preventive
effect in early postmenopausal women.
As the results of the randomized studies cannot be fully
translated to clinical practice, the Working Group on
Cardiovascular Disease in Women of the Societa’ Italiana
di Cardiologia has developed an expert document on the
cardiovascular effect of ERT/HRT. The primary aim of
this document is to highlight the risks and benefits
associated with the use of ERT/HRT in early postme-
nopausal women.
Menopause as cardiovascular risk factor
In postmenopausal women, ovarian hormone deficiency
induces changes in metabolic and hemodynamic func-
tions, leading to a greater prevalence of hypertension,
diabetes, hyperlipidemia and metabolic syndrome com-
pared with the premenopausal period [2]. Menopause is
associated with unfavorable changes in body weight and
body fat distribution, insulin sensitivity, plasma lipid
profile and sympathetic tone [15,16]. These modifi-
cations interact with each other, amplifying the primary
effect of ovarian hormone deficiency and the negative
consequence of aging. Postmenopausal women tend to
gain weight starting within the first year of amenorrhea
and their body fat is redistributed from a gynoid to an
android pattern [11–17]. The causal relationship
between body weight gain and estrogen deprivation is
suggested by the evidence that women taking HRT have
controlled BMI and their gynoid pattern of fat distri-
bution [11–17] is preserved much better than women not
on HRT. Increase in BMI and an increased proportion of
visceral fat are strongly correlated with the development
of arterial hypertension, insulin resistance and with a
range of metabolic risk factors for CVD [18]. Accordingly,
the improvement in insulin sensitivity produced by
weight loss, exercise and insulin sensitizers is associated
with a decrease in blood pressure values and improve-
ment in endothelial function [18–20]. Because of the
unfavorable changes related to the increase in body fat
and body fat redistribution, lifestyle changes, including
exercise programs and diet are one of the most important
preventive strategies for cardiovascular disease in
women. Studies conducted in Europe have almost invari-
ably shown a clear effect of exercise and diet on cardi-ovascular risk in women and that the effect of these
interventions is sustained for long-term [20]. Conversely
most US studies have failed to show an adequate adher-
ence to rehabilitation programs in women. These differ-
ences may be related to different cultural backgrounds
and lifestyles but must suggest lifestyle changes as the
primary intervention to counteract the increase in CVD
risk occurring with menopause. However, more recently,
data from the WHI in 73 743 postmenopausal women
aging 50–79 years have shown that that both walking and
vigorous exercise are associated with substantial
reductions in the incidence of cardiovascular events
among postmenopausal women, and that this effect
was present irrespective of race or ethnic group, age
and BMI [21].
Although after the menopause the lipoprotein profile
changes become more atherogenic, the importance of
lipid changes occurring after the menopause has been
overestimated in the past [22]. Serum concentrations of
triglycerides, total cholesterol, low-density lipoprotein
(LDL) and lipoprotein [Lp(a)] rise sharply within 6
months of menses cessation, whereas concentration of
high-density lipoprotein (HDL) declines gradually [22].
However, like themajority of risk factors, changes in lipid
profile are sex-specific and characterized by a different
relative importance in men and women [23]. In women
high triglycerides, Lp(a) and low HDL cholesterol levels
are more important than total and LDL cholesterol in the
development of CVD. Moreover, studies evaluating the
effect of lipid-lowering therapy have failed to show any
significant effect of these drugs in the reduction of
cardiovascular mortality and morbidity in women at
mild-to-moderate cardiovascular risk. Because of the
mild effect of statins in preventing CVD in women with
moderately elevated cholesterol, it has been calculated
that, for primary prevention, the cost of therapy per life
saved in women is significantly higher than that in men
(1.500.000 vs. 250.000 EURO) and, therefore, has an
unfavorable cost/benefit profile.
Arterial hypertension represents the single most import-
ant risk factor in elderly women, especially when coupled
with insulin resistance or diabetes [24,25]. Blood pressure
increases with age and, following middle age, both sys-
tolic and diastolic blood pressure appear to be higher in
women than in men. Although before the age of 50 years
arterial hypertension is more prevalent in men, by the age
of 65 almost 60% of women become hypertensive [24].
The finding that postmenopausal women have higher
systolic and diastolic blood pressure values than preme-
nopausal women of the same age, suggests a negative
effect of ovarian hormonal deprivation, which appears to
be additional and independent of the aging process.
However, the precise, single effect of menopause on
blood pressure is difficult to evaluate, because both
menopause and blood pressure are associated with aging
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economic status and smoking [24]. Arterial hypertension
in women is more frequent after the menopause and,
after stratification for age and BMI, the odds of having
hypertension are 2.2 after the menopause compared with
premenopausal age [24]. Several possible mechanisms
may explain the increase in blood pressure occurring after
the menopause. In addition to the unfavorable changes in
body weight and insulin resistance, postmenopausal
estrogen deficiency may affect the balance between
various vasoactive hormones, as well as the normal func-
tion of vascular smooth muscle cells. Also the increase in
salt sensitivity and the activation of the rennin–angio-
tensin–aldosterone system (RAAS) occurring after the
menopause play a significant role in the development of
arterial hypertension [26]. Arterial hypertension has a
greater impact on cardiovascular mortality and morbidity
in women than in men and hypertensive women are four
times more likely to develop CVD than age-matched
normotensive individuals [25]. Conversely to what
observed with interventions with hypolipidemic drugs,
all therapeutic strategies aimed at reducing blood pres-
sure levels have shown a beneficial effect on cardiovas-
cular events in women as in men. Furthermore, in
patients with metabolic syndrome an aggressive
reduction in blood pressure is more effective in women
than in men in reducing cardiovascular events [27].
Hormone replacement therapy and cardioprotection
As ovarian hormone deficiency is associated with unfa-
vorable changes in a broad range of risk factors for
cardiovascular disease and as ovarian hormone replace-
ment improves these changes, it has been suggested that
HRTmay confer cardioprotection. Since the late 70s and
until the publication of the WHI, estrogen and estro–
progestin replacement therapy have been widely pre-
scribed in early postmenopausal women for the relief
of menopausal symptoms. In the 90s, their use was
extended, in particular in the United States, to several
years after menopause with the understanding that both
replacement regimens might reduce the occurrence of
CVD. This belief was supported by the large body of
evidence demonstrating a favorable effect of ovarian
hormones on lipid profile and vascular function and by
several observational studies showing a significant
reduction in cardiovascular events with ERT and HRT
[5–10]. Because of the supposed benefit in primary
prevention, it has been hypothesized that HRT may
be beneficial in postmenopausal women with coronary
artery disease. However, the HERS study [28] failed to
show any protective effect of HRT in late postmenopau-
sal women (mean age 67.5 years) with proven coronary
artery disease. The study [28] has also suggested a
potential initial harm of HRT when started in late post-
menopausal women with proven cardiovascular disease;
however, this initial harm was not seen in those women
receiving satins.More recently the presentation to the lay press and to
the scientific community of the results of the WHI has
generated confusion regarding the cardiovascular effect
of HRT in postmenopausal women [29]. The WHI is a
National Institute of Health (NIH) sponsored study
aimed at evaluating the effect of ERT/HRT with
conjugated equine estrogens and medroxyprogesterone
acetate and other preventive strategies on several out-
comes in a population of women not usually prescribed
with HRT, namely late postmenopausal free of meno-
pausal symptoms. The mean age of women included in
the WHI study was 63.3 years; however, the vast
majority of women were of more than 60 years of
age at inclusion and more than 30% were above 70 years
of age. The study included one arm evaluating the
effect of estrogen/progestin HRT in women with a
uterus and one arm evaluating the effect of ERT with
conjugated equine estrogens. The estrogen–progestin
arm of the study was discontinued because of a sup-
posed increase in the Global Index [13], an index of
cumulative events that has never been validated and
whose definition has been changed several times
throughout the study. The estrogen only arm of the
study had been stopped 2 years thereafter without any
sound specific reason [14].
In contradiction to the wealth of data, the WHI study
found a number of results concordant with those of the
observational studies but instead of documenting a
protective effect of HRT against CHD, it set a warning
on a possible increase in CVD risk induced by such
therapy in late postmenopausal women [13,14]. How-
ever, the initial findings of the possible increased
cardiovascular risk suggested by the estrogen/progestin
arm of the study have not been confirmed by the
estrogen only arm of the study [14]. Overall the
WHI showed that ERT and HRT do not reduce
cardiovascular events in late postmenopausal women
[29]. However, the study has shown that in early
postmenopausal women, those within 10 years since
menopause, ERT and HRT have no arm [30]. Further-
more, the recent analysis of the two arms of the study
suggested a possible benefit of ERT on total mortality
in postmenopausal women in whom replacement
therapy was started before the age of 60 years [30].
This analysis also suggested that in early postmeno-
pausal women – women very similar to those included
in the observational studies and those who have always
been prescribed with HRT in Europe and in Italy –
ERT may reduce cardiovascular risk.
It is important to underline that the combined WHI trials
showed an overall increase risk of stroke with both ERT
and HRT. This increased risk, albeit not significantly
increased in the combined analysis of the ERT/HRT
arms, was not observed in those women of 50–59 years of
age at the start of ERT [30].
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ERT/HRT in early postmenopausal women and a
possible beneficial effect of ERT is also supported by
the results of the WHI-Coronary Artery Calcium Study
(WHI-CACS) [30]. The study, which is a sub-study of the
WHI aimed at assessing the effect of HRT on the
progression of atherosclerosis, has shown that ERT/
HRT in women aged 50–59 years significantly reduces
the degree of coronary calcifications [30]. Therefore, the
overall results of the WHI study on cardiovascular out-
comes suggest that two factors, time to initiation of HRT
since menopause and estrogen/progestin associations, are
of importance to explain the widely divergent findings on
the cardiovascular effects of observational studies and
randomized controlled studies.
An important difference between the observational and
randomized studies is represented by the characteristics
of participants recruited. Women included in the obser-
vational studies chose to take ovarian hormones because
of menopausal symptoms, on the contrary, in the random-
ized trials the absence of menopausal symptoms was a
prerequisite for inclusion in the study. In Italy, the mean
age at start of ERT/HRT is 52.6 years, 10 years less than
that in the WHI study. Studies performed in Italy
reported that less than 1% of women attending meno-
pause clinics had features similar to those included in the
randomized studies [31,32].
Clinical and experimental evidence suggests that most of
the cardioprotective and antiatherogenic effects of ovar-
ian hormones are receptor-mediated and endothelium-
dependent [33–41]. Experimental studies conducted on
monkeys indicated that estrogen administration delays
atherosclerosis progression if administered soon after
menopause but has no effect if given late. One possible
explanation for the lack of an effect of estrogens late after
menopause is related to the age-related increase in meth-
ylation of the promoter region of the estrogen receptors,
as well as of the estrogen receptors in vascular areas with
atherosclerosis [35,42,43]. This process diminishes the
estrogen-receptor-mediated effects attenuating or abol-
ishing the protective effect of estrogens on the vessel
wall. It has been shown that estrogen-receptor expression
in the arterial wall diminishes sharply with time since
menopause [35,43]. Furthermore, atherosclerotic human
coronary arteries show a greatly reduced density of estro-
gen receptors with estrogen deficiency [44–46]. Thus,
women who have been postmenopausal for several years
are clearly exposed to a longer period of ovarian hormone
deprivation thatmay lead to a reducednumber and activity
of vascular estrogen receptors. In addition, they could have
accumulated more extensive atherosclerotic damage
or developed endothelium dysfunction, resulting in an
overall reduced vascular responsiveness to estrogens. It
has been shown that time since menopause (>5 years)
influences vascular response to estrogens and, inwomen ofmore than 60 years of age, ERT/HRT may increase the
vascular inflammatory response [47–52].
It is well known that menopause negatively influences
BMI, glucose metabolism, blood pressure and coagu-
lation, increasing the likelihood of venous thromboem-
bolism (VTE).Women included in theWHI studies were
mostly overweight or obese. The association of late
menopause with increased body weight and oral HRT
may have heightened the risk of VTE observed in the
study. A long time since menopause is associated with a
reduced protective effect of estrogens, in presence of an
unaltered unfavorable effect upon coagulation shifting
the balance toward a procoagulant effect. Therefore,
whereas in early postmenopausal women ERT/HRT
may be cardioprotective because of the favorable respon-
siveness of the endothelium to estrogens, which buffers
the possible detrimental effect upon coagulation, in late
postmenopausal women ovarian hormones have either a
neutral or even a detrimental effect because of the
predominance of the inflammatory, procoagulant or pla-
que-destabilizing effects over the vasoprotective effects.
It is well known that estrogens may have a procoagulant
effect. However, the thromboembolic risk in women
receiving ERT/HRT has been overemphasized after
the WHI study. Indeed, the absolute risk of VTE with
ERT/HRT is very less because of the extremely low
prevalence of the disease. Although genetic polymorph-
isms may contribute to estrogen-associated increase in
prothrombotic risk in women receiving ERT/HRT, most
of these women have already been exposed to greater
procoagulant stimuli like pregnancy (nine-fold increase)
or oral contraception during their fertile life [53–55].
Therefore, the majority of women eligible to receive
HRT have undergone a physiological screening for pro-
thrombotic mutations during their fertile life and the risk
of undiagnosed polymorphisms for thrombophilia is
extremely low in postmenopausal women. Recently,
the Estrogen and Thromboembolism Risk (ESTHER)
study has suggested that BMI, diabetes and venous
insufficiency were the most important predictors of
VTE in women receiving HRT [56,57]. The risk of
VTE with HRT was also increased by cigarette smoking
and presence of prothrombotic mutations [57]. More
recently, the investigators of the ESTHER study have
suggested that different estrogen–progestin associations
and different routes of administration may have different
effects on the risk of thrombosis associated with HRT
[58]. The ESTER study was not designed to detect
differences between treatments and, therefore, these
latter results should be taken with caution.
Hormone regimen
The somewhat divergent results of the ERT and HRT
arms of the WHI have highlighted the importance of
the hormone regimen. The unfavorable effects of the
CE: Tripti; JCM/200672; Total nos of Pages: 8;
Hormone replacement therapy and cardioprotection Rosano et al. 5estrogen/progestin combination used in the randomized
studies appear to be related not to the hormone prep-
aration per se but to the use of that hormone regimen in
the wrong group of women. Indeed, it is well known that
the vascular effects of hormones may differ in women
with different time since menopause and with different
clinical characteristics [47–51]. Most of the women
included in the studywere hypertensive and themajority
of them were inadequately treated as only a small
minority had target blood pressure levels. The use of a
progestin with amineralocorticoid effect in hypertensive
women or in those at increased risk of hypertension was
associated with an increase in blood pressure levels that
per semay be responsible for some of the negative effects
like stroke seen in the late postmenopausal women –
those ofmore than 60 years of age.Medroxyprogesterone
acetate is seldom used in Europe and the association of
conjugated equine estrogens and medroxyprogesterone
acetate is not in the Italian market. In Europe, HRT
formulations contain different dosage of estrogens and a
wide range of progestins and newer progestin-like dros-
pirenone have been shown to reduce blood pressure in
hypertensive women receiving antihypertensive medi-
cations [58–61].
Women receiving HRT in Europe are different and are
managed differently from those in the United States and,
therefore, a careful selection of women to prescribe with
HRT by the gynecologists together with the appropriate
choice of HRT regimens may minimize risk and increase
the benefits. The WHI investigators acknowledged that
in women of 50–59 years of age, ERT/HRT may reduce
the overall mortality [30]. This statement represents a U
turn in the analysis of the WHI and moves toward a
European interpretation of the effect of ERT/HRT [62].
In fact, replacement therapy in Europe and in Italy is
utilized and it has always been prescribed for women of
age less than 60 years and in presence of menopausal
complaints.
One important point of relevance for the cardiologist is
represented by women with elevated cardiovascular risk.
The Cardiovascular Health Study [41] found that women
with multiple cardiovascular risk factors seem to have a
reduced vascular response to estrogens. Women recruited
in the randomized studies had a high incidence of uncon-
trolled risk factors such as arterial hypertension and
obesity compared with women included in the observa-
tional studies. This condition may have reduced the
effectiveness of the cardioprotective effect of estrogens
and increased the negative cerebrovascular effects of
progestins related to their mineralcorticoid-like effects
upon blood pressure. The effect of HRT upon blood
pressure is a very relevant issue as the changes in systolic
blood pressure observed in individuals randomized to
such treatment in WHI are likely to explain the small
increase in stroke in elderly women included in the study.As mentioned, women included in the WHI had often
uncontrolled arterial hypertension; this circumstancemay
have heightened the mineralcorticoid effect of medrox-
yprogesterone. The mineralcorticoid effect of progestins
may be enhanced by the effect of estrogens on the
production of angiotensinogen that in turn may increase
the production of angiotensin and aldosterone. There-
fore, progestins with antimineralcorticoid and antialdos-
terone effects should be preferred in the treatment of
postmenopausal women, especially if they have family
history of arterial hypertension or if they report weight
gain or bloating with other estrogen/progestin combi-
nations.
Hormone replacement therapy and cancer risk
Despite the fact that breast cancer is a rare cause of death
in women after the age of 50 years compared with
cardiovascular disease (6/100 deaths compared with 72/
100 breast cancer vs. cardiovascular disease in women
50 years of age or more). After the publication of WHI a
lot of attention. A major difference when discussing
cardiovascular and breast cancer risk is that cardiovascular
disease also includes mortality for cardiovascular events,
whereas breast cancer statistics reports only the occur-
rence of breast cancer. Furthermore, to date there is no
evidence that HRTmay increase the risk of death related
to breast cancer.
The degree of association between breast cancer and
postmenopausal HRT remains a major but still contro-
versial issue. All the hypothetical risks of HRT in peri-
menopausal women are definitely low, falling in the rare
category for the criteria of the Council for International
Organizations of Medical Sciences (CIOMS) [63].
Women should be reassured that the possible risk of
breast cancer associated with HRT is less (less than
0.1% per annum) [64]. Available evidence suggests that
HRT for less than 5 years has little, if any, impact on
breast cancer risk. In the WHI, this increased risk, in
absolute terms, was in the rare category, being 4–6
additional invasive cancers per 10 000 women per year
of HRT use for 5 or more years [13]. The increase in
breast cancer risk was significantly related to HRT use
before the participation in the trial, and confined to
women using HRT for 5–10 years before the 5.2 years
of the WHI duration [13]. There are insufficient data to
evaluate the possible differences in the incidence of
breast cancer using different types and routes of estrogen,
natural progesterone and progestogens and androgen
administration [64]. However, in the estrogen only arm
of the WHI, no increase in risk of breast cancer was
demonstrated after an average of 7.1 years of use, with six
fewer cases of invasive breast cancer per 10 000womenper
year of estrogen alone use, which is not statistically sig-
nificant [14]. As far as the uterine effects of HRT are
concerned, the use of unopposed systemic estrogen in
postmenopausal womenwith an intact uterus is associated
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to the dose and duration of use. Adequate concomitant
progestogen administration completely abolishes this risk
[30,64]. Continuous combined estrogen–progestogens
regimens are associated with a lower incidence of endo-
metrial hyperplasia and cancer than occurs in the normal
population.
Regarding the long-term effects of HRT on cancer inci-
dence, there is an increasing body of evidence suggesting
a protective effect of HRT not only on colon cancer but
also on lung cancer [30,65–69]. So far, the relevance of
the HRT protective effect (25% risk reduction) on lung
cancer (no.1 killer for cancer death in women) has been
overlooked by the medical community as well as by the
media coverage [70]. Therefore, physicians and consu-
mers are not aware of these important positive actions of
HRT on cancer risks. These issues should be fully
explained when HRT use is discussed with the women
concerned about HRT use.
Conclusion
In conclusion, the results of theWHI show that in women
of less than 60 years of age, ERT/HRT is safe from a
cardiovascular standpoint and may be prescribed without
fear. The cardiologist, however, should not prescribe
ERT/HRT for women, as this must be initiated by the
gynecologist according to the clinical presentation. Car-
diologists should counsel gynecologists for the control of
cardiovascular risk factors and give advice for the choice
of the more appropriate estrogen/progestin combination
and the adjunctive therapy to curb cardiovascular risk
according to the risk profile of each woman.
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